Navigation Links
PET/CT shows clear advantages over conventional staging for breast cancer patients
Date:1/2/2013

Reston, Va. (January 2, 2013) New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic stratification information at initial staging for patients with locally advanced breast cancer. When compared to conventional imaging, 18F-FDG PET/CT more accurately showed lesions in the chest, abdomen and bones in a single session, changing management for more than 50 percent of the patients in the study.

Guidelines from the National Comprehensive Cancer Network (NCCN) recommend a physical examination, bilateral mammogram, sonography or breast magnetic resonance (MR) imaging to examine the breast, as well as chest diagnostic CT, abdominal or pelvic diagnostic CT or MR imaging and bone scanning for evaluation of distant involvement. The NCCN guidelines consider 18F-FDG PET/CT to be "most helpful in situations where standard staging studies are equivocal or suspicious."

"The prognosis of patients with locally advanced breast cancer remains poor. In this study we aimed to investigate whether the use of 18F-FDG PET/CT at initial staging could have an impact on the prognostic stratification and management of patients with locally advanced breast cancer," said David Groheux, MD, PhD, lead author of the study "18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging."

One hundred and seventeen patients with locally advanced breast cancer were prospectively included in the study over a course of five years. Patients underwent conventional imaging methods, including bone scanning, chest radiography, or dedicated CT and abdominopelvic examination by sonography or contrast-enhanced CT and were staged accordingly. They then received an 18F-FDG PET/CT scan, which was reviewed by nuclear medicine specialists with no knowledge of the conventional imaging results. The conventional imaging and 18F-FDG imaging results were then compared.

All primary tumors were identified by 18F-FDG PET/CT. The scans confirmed lymph node involvement in stage IIIC patients and revealed unsuspected lymph node involvement in 32 additional patients. Furthermore, distant metastases (bone, distant lymph nodes, liver, lung and pleura) were visualized with 18F-FDG PET/CT in 43 patients; conventional imaging only identified 28 patients with distant metastases. Overall, 18F-FDG PET/CT changed the stage of 61 out of 117 patients, which, in turn, impacted the recommended treatment for the patients.

"This is a step toward the truly personalized medicine that molecular imaging can bringacquiring an image that provides sufficient information to truly tailor management strategies to the singular needs of each patient," noted Groheux. "Based on these findings, 18F-FDG PET/CT may become the single most important distant staging modality in patients with locally advanced breast cancer."


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Study examines necessity of additional imaging in PET/CT oncologic reports
2. Benefit of PET and PET/CT in ovarian cancer is not proven
3. Pretreatment PET/CT imaging of lymph nodes predicts recurrence in breast cancer patients
4. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
5. Wellesley study shows income inequality a key factor in high US teen births
6. Invasive heart test being dramatically overused, Stanford study shows
7. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
8. Lung Cancer Screening Might Pay Off, Analysis Shows
9. Nonsurgical Method to Measure Brain Pressure Shows Promise
10. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
11. Study Shows New Option for Kids With Tough-to-Treat Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point to lead ... reduce waste, and support renewable energy. They believe this is a crucial part of ... solutions for health issues, and maintain that destroying the environment in the pursuit of ...
(Date:4/24/2017)... ... ... , a national non-profit organization focusing on the prevention and early detection of breast and ... to announce Katie Thiede as their new Chief Executive Officer. In January, founder Lindsay Avner ... Board and launched a national search to find a visionary new leader to grow Bright ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum of Health and ... to track their cognitive health, and share results with their physicians. Members and guests ... the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... within the telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick ... Available 24 hours a day, Quick Care provides patients with the option to ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced today ... people with addiction who are served by MAP’s patient engagement ecosystem. Lief Therapeutics ... monitors heart and breath rates to identify anxiety levels and can provide biofeedback ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: